Growth hormone control of hepatic lipid metabolism

Zhongbo Liu, Jose Cordoba-Chacon, Rhonda D. Kineman, Bruce N. Cronstein, Radhika Muzumdar, Zhenwei Gong, Haim Werner, Shoshana Yakar

Research output: Contribution to journalArticle

Abstract

In humans, low levels of growth hormone (GH) and its mediator, IGF-1, associate with hepatic lipid accumulation. In mice, congenital liver-specific ablation of the GH receptor (GHR) results in reductions in circulating IGF-1 and hepatic steatosis, associated with systemic insulin resistance. Due to the intricate relationship between GH and IGF-1, the relative contribution of each hormone to the development of hepatic steatosis is unclear. Our goal was to dissect the mechanisms by which hepatic GH resistance leads to steatosis and overall insulin resistance, independent of IGF-1. We have generated a combined mouse model with liver-specific ablation of GHR in which we restored liver IGF-1 expression via the hepatic IGF-1 transgene. We found that liver GHR ablation leads to increases in lipid uptake, de novo lipogenesis, hyperinsulinemia, and hyperglycemia accompanied with severe insulin resistance and increased body adiposity and serum lipids. Restoration of IGF-1 improved overall insulin sensitivity and lipid profile in serum and reduced body adiposity, but was insufficient to protect against steatosis-induced hepatic inflammation or oxidative stress. We conclude that the impaired metabolism in states of GH resistance results from direct actions of GH on lipid uptake and de novo lipogenesis, whereas its actions on extrahepatic tissues are mediated by IGF-1.

Original languageEnglish (US)
Pages (from-to)3598-3609
Number of pages12
JournalDiabetes
Volume65
Issue number12
DOIs
StatePublished - Dec 1 2016

Fingerprint

Lipid Metabolism
Growth Hormone
Insulin-Like Growth Factor I
Liver
Insulin Resistance
Lipids
Lipogenesis
Adiposity
Somatotropin Receptors
Hyperinsulinism
Serum
Transgenes
Hyperglycemia
Oxidative Stress
Hormones
Inflammation

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Liu, Z., Cordoba-Chacon, J., Kineman, R. D., Cronstein, B. N., Muzumdar, R., Gong, Z., ... Yakar, S. (2016). Growth hormone control of hepatic lipid metabolism. Diabetes, 65(12), 3598-3609. https://doi.org/10.2337/db16-0649

Growth hormone control of hepatic lipid metabolism. / Liu, Zhongbo; Cordoba-Chacon, Jose; Kineman, Rhonda D.; Cronstein, Bruce N.; Muzumdar, Radhika; Gong, Zhenwei; Werner, Haim; Yakar, Shoshana.

In: Diabetes, Vol. 65, No. 12, 01.12.2016, p. 3598-3609.

Research output: Contribution to journalArticle

Liu, Z, Cordoba-Chacon, J, Kineman, RD, Cronstein, BN, Muzumdar, R, Gong, Z, Werner, H & Yakar, S 2016, 'Growth hormone control of hepatic lipid metabolism', Diabetes, vol. 65, no. 12, pp. 3598-3609. https://doi.org/10.2337/db16-0649
Liu Z, Cordoba-Chacon J, Kineman RD, Cronstein BN, Muzumdar R, Gong Z et al. Growth hormone control of hepatic lipid metabolism. Diabetes. 2016 Dec 1;65(12):3598-3609. https://doi.org/10.2337/db16-0649
Liu, Zhongbo ; Cordoba-Chacon, Jose ; Kineman, Rhonda D. ; Cronstein, Bruce N. ; Muzumdar, Radhika ; Gong, Zhenwei ; Werner, Haim ; Yakar, Shoshana. / Growth hormone control of hepatic lipid metabolism. In: Diabetes. 2016 ; Vol. 65, No. 12. pp. 3598-3609.
@article{b2fe22205bd148dd998da7ea8a845f6a,
title = "Growth hormone control of hepatic lipid metabolism",
abstract = "In humans, low levels of growth hormone (GH) and its mediator, IGF-1, associate with hepatic lipid accumulation. In mice, congenital liver-specific ablation of the GH receptor (GHR) results in reductions in circulating IGF-1 and hepatic steatosis, associated with systemic insulin resistance. Due to the intricate relationship between GH and IGF-1, the relative contribution of each hormone to the development of hepatic steatosis is unclear. Our goal was to dissect the mechanisms by which hepatic GH resistance leads to steatosis and overall insulin resistance, independent of IGF-1. We have generated a combined mouse model with liver-specific ablation of GHR in which we restored liver IGF-1 expression via the hepatic IGF-1 transgene. We found that liver GHR ablation leads to increases in lipid uptake, de novo lipogenesis, hyperinsulinemia, and hyperglycemia accompanied with severe insulin resistance and increased body adiposity and serum lipids. Restoration of IGF-1 improved overall insulin sensitivity and lipid profile in serum and reduced body adiposity, but was insufficient to protect against steatosis-induced hepatic inflammation or oxidative stress. We conclude that the impaired metabolism in states of GH resistance results from direct actions of GH on lipid uptake and de novo lipogenesis, whereas its actions on extrahepatic tissues are mediated by IGF-1.",
author = "Zhongbo Liu and Jose Cordoba-Chacon and Kineman, {Rhonda D.} and Cronstein, {Bruce N.} and Radhika Muzumdar and Zhenwei Gong and Haim Werner and Shoshana Yakar",
year = "2016",
month = "12",
day = "1",
doi = "10.2337/db16-0649",
language = "English (US)",
volume = "65",
pages = "3598--3609",
journal = "Diabetes",
issn = "0012-1797",
publisher = "American Diabetes Association Inc.",
number = "12",

}

TY - JOUR

T1 - Growth hormone control of hepatic lipid metabolism

AU - Liu, Zhongbo

AU - Cordoba-Chacon, Jose

AU - Kineman, Rhonda D.

AU - Cronstein, Bruce N.

AU - Muzumdar, Radhika

AU - Gong, Zhenwei

AU - Werner, Haim

AU - Yakar, Shoshana

PY - 2016/12/1

Y1 - 2016/12/1

N2 - In humans, low levels of growth hormone (GH) and its mediator, IGF-1, associate with hepatic lipid accumulation. In mice, congenital liver-specific ablation of the GH receptor (GHR) results in reductions in circulating IGF-1 and hepatic steatosis, associated with systemic insulin resistance. Due to the intricate relationship between GH and IGF-1, the relative contribution of each hormone to the development of hepatic steatosis is unclear. Our goal was to dissect the mechanisms by which hepatic GH resistance leads to steatosis and overall insulin resistance, independent of IGF-1. We have generated a combined mouse model with liver-specific ablation of GHR in which we restored liver IGF-1 expression via the hepatic IGF-1 transgene. We found that liver GHR ablation leads to increases in lipid uptake, de novo lipogenesis, hyperinsulinemia, and hyperglycemia accompanied with severe insulin resistance and increased body adiposity and serum lipids. Restoration of IGF-1 improved overall insulin sensitivity and lipid profile in serum and reduced body adiposity, but was insufficient to protect against steatosis-induced hepatic inflammation or oxidative stress. We conclude that the impaired metabolism in states of GH resistance results from direct actions of GH on lipid uptake and de novo lipogenesis, whereas its actions on extrahepatic tissues are mediated by IGF-1.

AB - In humans, low levels of growth hormone (GH) and its mediator, IGF-1, associate with hepatic lipid accumulation. In mice, congenital liver-specific ablation of the GH receptor (GHR) results in reductions in circulating IGF-1 and hepatic steatosis, associated with systemic insulin resistance. Due to the intricate relationship between GH and IGF-1, the relative contribution of each hormone to the development of hepatic steatosis is unclear. Our goal was to dissect the mechanisms by which hepatic GH resistance leads to steatosis and overall insulin resistance, independent of IGF-1. We have generated a combined mouse model with liver-specific ablation of GHR in which we restored liver IGF-1 expression via the hepatic IGF-1 transgene. We found that liver GHR ablation leads to increases in lipid uptake, de novo lipogenesis, hyperinsulinemia, and hyperglycemia accompanied with severe insulin resistance and increased body adiposity and serum lipids. Restoration of IGF-1 improved overall insulin sensitivity and lipid profile in serum and reduced body adiposity, but was insufficient to protect against steatosis-induced hepatic inflammation or oxidative stress. We conclude that the impaired metabolism in states of GH resistance results from direct actions of GH on lipid uptake and de novo lipogenesis, whereas its actions on extrahepatic tissues are mediated by IGF-1.

UR - http://www.scopus.com/inward/record.url?scp=85000838194&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85000838194&partnerID=8YFLogxK

U2 - 10.2337/db16-0649

DO - 10.2337/db16-0649

M3 - Article

VL - 65

SP - 3598

EP - 3609

JO - Diabetes

JF - Diabetes

SN - 0012-1797

IS - 12

ER -